PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19166694-7	2009	The combination of nicotinic acid and gemfibrozil reduced atherogenic by IDL 71%, dense LDL-III by 52%, and apolipoprotein B by 37% and increased protective HDL(2) by 90%.	Gemfibrozil	38-49	junctophilin 3	Homo sapiens	157-163	
7578896-5	1995	In the gemfibrozil-treated group a significant decrease of total cholesterol and triglycerides and a significant increase of HDL-C and HDL2-C were found.	Gemfibrozil	7-18	junctophilin 3	Homo sapiens	135-139	
8595642-5	1995	Gemfibrozil significantly decreased triglyceride, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein (IDL) levels, the total cholesterol:HDL ratio, and the IDL plus VLDL;HDL ratio, and significantly increased levels of HDL, HDL2, and HDL3.	Gemfibrozil	0-11	junctophilin 3	Homo sapiens	247-251	
7755644-9	1995	Furthermore, gemfibrozil increased HDL cholesterol (P < 0.05) and normalised the elevated HDL2 and HDL3 TG content.	Gemfibrozil	13-24	junctophilin 3	Homo sapiens	93-97	
1613316-3	1992	Gemfibrozil and lovastatin caused primarily similar alterations in HDL components in HDL2 and HDL3 subfractions.	Gemfibrozil	0-11	junctophilin 3	Homo sapiens	85-89	
1613316-6	1992	Gemfibrozil increased the cholesterol concentrations of HDL2 and HDL3 (p less than 0.05 for both), and lovastatin caused significant increases in HDL2 (p less than 0.05) and HDL3 phospholipids (p less than 0.01).	Gemfibrozil	0-11	junctophilin 3	Homo sapiens	56-60